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Abstract
Background. The majority of pancreatic tumors are primary. The pancreas can however be the site of metastasis from renal
cell cancer, lung, colon and breast cancers. The value of surgical treatment is unclear in such situations. The aim of this
study was to evaluate the outcome of surgical therapy in patients with isolated metastases to the pancreas. Methods. All
patients who underwent pancreatic surgery for malignant disease from 1999 to 2005 (n338) at the department of
hepatobiliary and pancreatic surgery, the Royal London Hospital, London, were evaluated from a retrospective pancreatic
database. Five patients had metastatic pancreatic cancer. Surgical outcome and survival were examined in this subset of
patients. Results. The primary cancer was renal cell carcinoma (n2), breast (n1), colon (n1) and ovarian (n1). The
two patients with renal cell carcinoma developed pancreatic metastases years from the primary diagnosis. Both patients are
alive 56 and 36 months post surgery. Two patients with breast and ovarian primary presented years after diagnosis of the
primary but had advanced unresectable disease. There was one patient with colonic primary and synchronous pancreatic
metastasis, and had a colectomy and Whipple’s operation, and is alive 64 months postoperatively. Conclusion. The pancreas
is an uncommon site for metastasis. Patients can present years after the treatment of primary. Long-term survival can be
achieved with pancreatic resection in a highly selected subset of patients, and patients with primary renal cell carcinoma
seem to have a favorable prognosis.
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Introduction
The vast majority of pancreatic tumors are primary
pancreatic adenocarcinoma; the pancreas can how-
ever be the site of metastases from renal cell cancer
along with lung, breast, and colon or skin tumors [1].
Metastatic carcinoma to the pancreas from another
site is uncommon and accounts for approximately 2%
of pancreatic malignancies [2]. In large autopsy series
the prevalence of pancreatic metastases has been
described to be as high as 6 to 11%, and renal cell
carcinoma appears to be the most common primary
tumor to cause secondary pancreatic tumors [3]. The
metastases may be single or multiple, synchronous or
metachronous (some time occurring very late). Pan-
creatic metastases must be distinguished from locor-
egional invasion of malignant gastrointestinal tumors
[4].
Although isolated metastatic disease to the pancreas
is relatively uncommon, there are select cases in which
this process does occur. Unfortunately, experience
with pancreatic resections for the treatment of isolated
metastatic lesions is very limited [5]. As a result there
are few guidelines that exist regarding the appropriate
management of such lesions. We report a series of five
cases of metastatic pancreatic tumors and the outcome
of surgical treatment with a review of the literature.
Patients and methods
All patients who underwent pancreatic surgery for
malignant disease from 1999 to 2005 (n338) at The
Royal London Hospital, were evaluated from a retro-
spective pancreatic database. Patient demographics
and clinical variables including the type of pancreatic
resection, primary histopathology and disease free
interval (the interval from the presentation of the
primary and development of pancreatic metastases)
were examined. Five patients had metastatic pancrea-
tic cancer. Surgical outcome and survival were exam-
ined in this subset of patients.
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Results
The primary cancer was renal cell carcinoma (n2),
breast (n1), and ovarian (n1). The two patients
with renal cell carcinoma developed pancreatic me-
tastases 8 and 14 years from the primary diagnosis.
One underwent distal pancreatectomy, and the other
distal pancreatectomy and splenectomy. Both patients
were alive 56 and 36 months post surgery (see Table
I). One patient with breast cancer presented nine years
after her primary was diagnosed. She was explored
with curative intent, but she had widespread pancrea-
tic and liver disease, so had a palliative bypass. She
survived six months postoperatively. One patient with
ovarian primary was diagnosed eight years after the
primary diagnosis. She had a solitary pancreatic
metastasis, but it was irresectable, so she had palliative
bypass. She is alive 65 months postoperatively; she had
cisplatin chemotherapy. There was one patient with
colonic primary and synchronous pancreatic metasta-
sis, and had colectomy and Whipple’s operation. He is
alive 44 months postoperatively (see Table I).
Discussion
The pancreas is an unusual but occasionally favored
site for metastases, notably from carcinoma of kidney
and lung [6]. In a clinical series of patients with
pancreatic tumors, 4.5% of the cases were found to be
metastases, and that figure increased to 42% among
patients with previously diagnosed primary cancers
and a solitary mass of the pancreas [7,8].
The symptoms from neoplasms of the pancreas
include pain, weight loss and obstructive jaundice.
Upper gastrointestinal bleeding and acute pancreatitis
are less common but well-recognized in patients with
primary pancreatic cancer. Although many patients
with pancreatic metastasis have widespread disease,
isolated metastases can be found [9]. If isolated
metastases in the pancreas become symptomatic,
they are often misdiagnosed as primary pancreatic
adenocarcinoma.
Preoperative diagnosis is based on imaging. CT
scans and MRI support the diagnosis, especially if
multiple tumors are noted. Highly vascular tumors, as
indicated by contrast enhanced CT scan, MRI, or
angiography, are more likely to be metastases than
primary pancreatic cancers, which tend to be rela-
tively hypovascular. These findings are particularly
applicable to renal cell carcinoma.
Recently, an improvement in hospital perioperative
morbidity and mortality rates for pancreaticoduode-
nectomies has been documented and resections of
metastatic tumors have been reported [10,11].
Although isolated metastases from renal cell carci-
noma are rare, their behavior is often unusual because
some patients have an indolent natural history, with
presentation of metastatic renal cell carcinoma many
years after treatment. Two patients in our series
presented eight and 14 years after the diagnosis of
primary renal cell carcinoma. Similar findings were
noted by Sohn [2] and Law et al. [12] It is estimated
that between 2 and 6% of patients with renal cell
carcinoma are amenable to surgical resection [13].
Aggressive surgery for these isolated metastases has
been shown to significantly improve survival
[2,5,7,14].
Metastases are solitary in fewer than 10% of the
patients with metastatic renal cell carcinoma. Resec-
tion of isolated metastases may contribute to pro-
longed survival in a small group of these patients
[15,16]. It is difficult to determine long-term survival
following pancreatic resection accurately for meta-
static renal cell carcinoma. However, the results of
different case reports are encouraging with most
patients living more than one year after resection.
Our two patients are alive three and 4.5 years after
resection. Z’graggen et al. [7] have reported that three
patients were surviving for more than 20 months.
Sahin et al. [17] have reported that patients were
surviving for 18 and 22 months after pancreatic
resection.
One patient with colorectal primary in our series
presented with a synchronous lesion in pancreatic
Table I. Patient demographics and clinical variables.
No
Age and
sex
Site of primary
tumor
Interval between treatment
of primary and metastases
Tumor
characteristics Procedure performed Status
Survival
(months)
1 58/Male Renal cell
carcinoma
8 years Solitary tumor, body
of pancreas
Distal pancreatectomy Alive 56
2 64/Male Renal cell
carcinoma
14 years Solitary tumor, body
and tail of pancreas
Distal pancreatectomy
splenectomy
Alive 32
3 76/Female Breast cancer 9 years Pancreaticliver
metastasis
Palliative bypass Dead 6
4 70/Female Ovarian
cancer
8 years Large solitary tumor,
invading
vessels
Palliative bypass Alive 65
5 67/Male Colon cancer Synchronous lesion Colonpancreatic
head
Bowel resection
Whipple’s
Alive 44
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head and had synchronous colectomy and Whipple’s
operation. He is alive 44 months postoperatively.
There is little evidence in the literature to support
synchronous bowel and pancreatic resection.
Two patients with breast and ovarian primary
presented after a long disease free interval, but
preoperatively found to have more extensive disease,
so were not suitable for pancreatic resection. Crippa
et al. [9] have reported three patients having pancrea-
ticoduodenectomy for metastatic breast cancer asso-
ciated with more than 20 months of survival after
pancreatectomy.
A notable finding in our series was a long disease
free interval. This was particularly the case with renal
cell carcinoma patients. So the presence of pancreatic
mass or masses in a patient with previous history of
extra-pancreatic cancer is highly suggestive of pan-
creatic metastatic dissemination. Patients with iso-
lated renal cell carcinoma metastases to the pancreas,
whether synchronous or metachronous, represent a
select group of patients with more indolent renal cell
carcinoma. A history of previously resected metastases
should not discourage pancreatic resection, providing
the pancreas is the only site of metastases at the time
of surgery.
In summary, the pancreas is an uncommon site for
metastasis. Patients can present years after the treat-
ment of primary disease. Long-term survival can be
achieved with pancreatic resection in a highly selected
subset of patients, and patients with primary renal cell
carcinoma seem to have a favorable prognosis.
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